Stryker Corp. Stock
€311.80
Your prediction
Stryker Corp. Stock
Pros and Cons of Stryker Corp. in the next few years
Pros
Cons
Performance of Stryker Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Stryker Corp. | -2.740% | 1.267% | -2.226% | -14.388% | -10.787% | 46.902% | 59.049% |
| Henry Schein Inc. | -0.220% | -1.094% | 12.601% | -2.814% | -7.854% | -18.418% | 10.755% |
| Dexcom Inc. | -2.680% | 5.079% | -12.428% | -29.634% | -33.828% | -54.291% | -29.683% |
| Zimmer Holdings | -0.330% | 1.071% | -8.731% | -25.723% | -23.896% | -30.718% | -39.563% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financial performance of Stryker Corporation (SYK) in the Healthcare Equipment & Supplies industry presents a mixed bag of strengths and weaknesses. The company has showcased significant growth in revenues and net income over the past few years, demonstrating resilience in an evolving market. However, challenges related to profitability margins and high valuation ratios suggest a careful approach to investment. Let’s delve deeper into the key components of the financials to get a clearer picture of Stryker’s financial health.
*Pros: *
Revenue Growth: Stryker exhibited robust revenue growth year-over-year, going from $17.1 billion in 2021 to approximately $20.5 billion in 2023. This growth can be attributed to increasing demand for medical devices, innovations, and the company’s broad product portfolio, which includes surgical equipment, neurotechnology, and spine products.
Comments
News
Beware The Death Cross: 3 Stocks Triggering This Spooky Signal
There are two types of Halloween people: those who like jump scares and those who don’t. But even if you’re a fan of haunted hayrides and movies like The Conjuring, you probably don’t want to ever
Stryker (SYK) Q2 Revenue Jumps 11%
Stryker (NYSE:SYK), a leading global medical technology company, reported financial results on July 31, 2025. The company delivered several key beats: Net sales (GAAP) reached $6.0 billion, topping
